Turnstone Biologics (TSBX) Q3 2024 earnings summary

Executive summary

• The company prioritized the TIDAL-01 program for solid tumors, implementing a 60% workforce reduction and leadership changes to streamline operations.

• Three ongoing Phase 1 trials for TIDAL-01 target colorectal, head and neck, and uveal melanoma.

• Initial clinical data from the STARLING trial in MSS mCRC showed a 25% overall response rate and a durable complete response over one year.

• Corporate restructuring and portfolio prioritization are expected to extend the cash runway into Q2 2026.

Financial highlights

• Cash, cash equivalents, and short-term investments were $45.3 million as of September 30, 2024, down from $94.8 million at December 31, 2023.

• Net loss was $17.0 million for Q3 2024 and $58.0 million for the nine months ended September 30, 2024.

• R&D expenses were $14.4 million for Q3 2024, mainly due to increased TIDAL-01 clinical costs.

• G&A expenses decreased to $3.9 million in Q3 2024, reflecting lower personnel and professional service costs.

• No collaboration revenue was recognized in 2024 due to the termination of the Takeda agreement.

Outlook and guidance

• Cash runway is expected to fund operations into Q2 2026, but substantial doubt exists about the ability to continue as a going concern without additional capital.

• Management plans to seek additional funding through equity, debt, or partnerships.

• R&D and G&A expenses are expected to decrease following the restructuring.

• Next clinical update for TIDAL-01 is anticipated in the first half of 2025.